Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancerAzeem Saleem, C. Lowdell, Tomomi Kaneko et al.|EJNMMI Research|2015Cited by 77
Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)R. Charles Coombes, Stuart McIntosh, Sacha J. Howell et al.|Cancer Research|2022Cited by 7
Brain and tumor penetration of carbon-11–labeled lapatinib ([<sup>11</sup>C]Lap) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC).Azeem Saleem, R. Charles Coombes, Graham E. Searle et al.|Journal of Clinical Oncology|2013Cited by 5
Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)Sacha J. Howell, R. Charles Coombes, Laura Kenny et al.|Cancer Research|2022Cited by 5
Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancerAzeem Saleem, Graham E. Searle, Laura Kenny et al.|EJNMMI Research|2017Cited by 2